31846-95-4

Upstream product

• 1000986-46-8 C₁₇H₁₉NO₄S 
• 552-16-9 ortho-nitrobenzoic acid 
• 124-63-0 methanesulfonyl chloride 
• 100-51-6 benzyl alcohol 
• 134-20-3 2-carbomethoxyaniline 
• 716-41-6 methyl N-mesylanthranilate 
• 31846-94-3 methyl 2-(N-benzyl-N-methanesulfonylamino)benzoate 

Downstream Products

• 1000986-54-8 C₁₆H₁₂ClNO₃S 
• 1308887-75-3 3,3-dibromo-1-benzyl-1H-2,1-benzothiazin-4(3H)-one 2,2-dioxide 
• 1308887-76-4 3,3-dichloro-1-benzyl-1H-2,1-benzothiazin-4(3H)-one 2,2-dioxide 

Relevant academic research and scientific papers

Synthesis, characterization, monoamine oxidase inhibition, molecular docking and dynamic simulations of novel 2,1-benzothiazine-2,2-dioxide derivatives

In this research work, we report the synthesis and biological evaluation of two new series of 1-benzyl-4-(benzylidenehydrazono)-3,4-dihydro-1H-benzo[c] [1,2]thiazine 2,2-dioxides and 1-benzyl-4-((1-phenylethylidene)hydrazono)-3,4-dihydro-1H-benzo[c][1,2]t

Synthesis, X-ray crystal and monoamine oxidase inhibitory activity of 4,6-dihydrobenzo[c]pyrano[2,3-e][1,2]thiazine 5,5-dioxides: In vitro studies and docking analysis

We report the synthesis and biological evaluation of two new series of 2-amino-6-benzyl-4-phenyl-4,6-dihydrobenzo[c]pyrano[2,3-e][1,2]thiazine-3?carbonitrile 5,5-dioxides and 2-amino-6-methyl-4-phenyl-4,6-dihydrobenzo[c]pyrano[2,3-e][1,2]thiazine-3?carbon

Reactivity, Selectivity, and Stability in Sulfenic Acid Detection: A Comparative Study of Nucleophilic and Electrophilic Probes

The comparative reaction efficiencies of currently used nucleophilic and electrophilic probes toward cysteine sulfenic acid have been thoroughly evaluated in two different settings-(i) a small molecule dipeptide based model and (ii) a recombinant protein model. We further evaluated the stability of corresponding thioether and sulfoxide adducts under reducing conditions which are commonly encountered during proteomic protocols and in cell analysis. Powered by the development of new cyclic and linear C-nucleophiles, the unsurpassed efficiency in the capture of sulfenic acid under competitive conditions is achieved and thus holds great promise as highly potent tools for activity-based sulfenome profiling.

Synthesis and antifungal activity of halogen-substituted 2,1-Benzothiazine-2,2-dioxide derivatives

A convenient synthesis of a series of new halogen-substituted 2,1-benzothiazine-2,2-dioxide derivatives has been described. The starting compound un/substituted methyl anthranilate is converted into 2,1-benzothiazine-2,2-dioxide heterocyclic ring system v

A solid-phase synthetic method for 3,4-dihydro-1H-2,1-benzothiazin-4-one 2,2-dioxide derivatives

Utilizing polymer-bound anthranilic acid derivatives, we were able to obtain 3,4-dihydro-1H-2,1-benzothiazine-4-one 2,2-dioxide derivatives through N-methanesulfonylation by use of sulfonyl chloride, sulfonic acid, or sodium sulfonate, N-alkylation under Mitsunobu condition, and the cyclative cleavage in 8-52% five-step overall isolated yields and 91-99% purities from Wang resin. The reactions on solid phase were monitored by on-bead ATR-FTIR spectroscopic method and checked by help of solution-phase model experiments.

N-alkyl-4-chloro-1H-benzo[c][1,2]thiazine-3-carbaldehyde-2,2-dioxides - New functional benzothiazine derivatives

(Chemical Equation Presented) A synthesis of N-alkyl-4-chloro-1H-benzo[c] [1,2]thiazine-3-carbaldehyde-2,2-dioxides is described. Reactivity of new β-chloroaldehydes is investigated, a number of novel benzo[c][1,2]thiazine derivatives are synthesized and characterized using 1H, 13C-NMR, MS and elemental analysis.

CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Constrained compounds as CGRP-receptor antagonists

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.